Hepatitis

Hepatitis

WHO / Isaac Rudakubana

Chronic HCV infection remains a major cause of liver disease globally, with an estimated 71 million people living with chronic HCV overall as of 2015 and an estimated 1.75 million new cases per year. However, to date less emphasis has been placed on chronic HCV in children and the prevalence, epidemiology, and natural history of infection are less well understood in children than in adults. A recent review generated modelled estimates on prevalence of infection in children aged 1-18 years. Globally, there were an estimated 3.26 million children living with chronic HCV infection; and 20 countries accounted for 80% of all cases in patients 0-18 years of age. Countries with the highest number of children with chronic HCV were: Pakistan, China, India, Nigeria, and Egypt.

The predominant mode of acquisition of HCV infection in children is mother-to-child transmission, although older children and adolescents may become infected via unsafe injection practices or poor infection control practices. About 5% of infants born to mothers with HCV infection may acquire infection, which increases to up to 10% if the mother is co-infected with HIV. The risk of transmission increases with increasing maternal HCV RNA levels. Fortunately, the majority of cases in children are asymptomatic or minimally symptomatic,  and cirrhosis and hepatocellular carcinoma is rare in this age group. For this reason,  in the absence of regulatory approval and availability of formulations for pan-genoptyic DAA regimens, most professional society guidelines have recommended deferral of treatment t in younger children.

A recent global survey of policies on HCV testing and treatment in children found that most national HCV policies lack specific recommendations for HCV testing and treatment in children and adolescents, and only 33 countries had such recommendations. Updated guidance on testing and treatment is needed for younger age groups; and national elimination plans need to include case finding strategies and treatment programs for children as well as adults, children, especially those in countries with a high burden of HCV infection.

Portfolio products

3 products · PADO-hepatitis
● Access list: 0    ● Priority list: 1    ● Watch list: 2
0 Access
1 Priority
2 Watch

PADO-hepatitis priority list 1
SOF/DAC
PADO-hepatitis watch list 2
SOF/VEL
G/P

Related publications

Paediatric drug optimization standard procedure

The aim of this document is to provide guidance on how to undertake a paediatric drug optimization exercise and identify key priority products for research...

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021

This report provides accountability for the 3 Global Health Sector Strategies (2016-2021) on HIV, Viral Hepatitis and the STIs. The report assesses the...

Progress report on HIV, viral hepatitis and sexually transmitted infections 2019

WHO is accountable for reporting back to the World Health Assembly on progress in implementing the Global health sector strategies on HIV, viral hepatitis...

Guidelines on hepatitis B and C testing

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are major causes of acute and chronic liver disease (e.g. cirrhosis and hepatocellular carcinoma) globally,...

Guidelines on hepatitis B and C testing

These are the first WHO guidelines on testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and complement published guidance...

Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis

This is the first global health sector strategy on viral hepatitis, a strategy that contributes to the achievement of the 2030 Agenda for Sustainable Development.It...

Related publications

Contact

Asma Hafiz

Project Manager

Email: ahafiz@who.int

Martina Penazzato

Technical lead

Email: penazzatom@who.int

News